Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis

Archives of Surgery

Volumn 141, Issue 7, 2006, Pages 670-676

  Alsfasser, Guido ^a   Warshaw, Andrew L ^a   Thayer, Sarah P ^a   Antoniu, Bozena ^a   Laposata, Michael ^a   Lewandrowski, Kent B ^a   Fernández del Castillo, Carlos ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; GLYCODEOXYCHOLIC ACID; MYELOPEROXIDASE; SODIUM CHLORIDE;

ACUTE PANCREATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG APPROVAL; EXPERIMENTAL MODEL; FOOD AND DRUG ADMINISTRATION; HEMOCONCENTRATION; HISTOPATHOLOGY; INFLAMMATION; LEUKOCYTOSIS; MALE; MOUSE; NONHUMAN; PANCREAS NECROSIS; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAERULEIN; DISEASE MODELS, ANIMAL; FOLLOW-UP STUDIES; MALE; PANCREAS; PANCREATITIS, ACUTE NECROTIZING; PEROXIDASE; PROTEIN C; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33746086050     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.141.7.670     Document Type: Article

References (37)

1. Grinnell BW, Hermann RB, Yan SB. Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide. Glycobiology. 1994;4:221-225.
2. Arnljots B, Dahlback B. Antithrombotic effects of activated protein C and protein S in a rabbit model of microarterial thrombosis. Arterioscler Thromb Vasc Biol. 1995;15:937-941.
3. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med. 2001;29(suppl):S48- S51.
4. Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood. 1986;68:1218-1223.
5. Murakami K, Okajima K, Uchiba M, et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol. 1997;272:L197-L202.
6. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001;276:11199-11203.
7. Shibata M, Kumar SR, Amar A, et al. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation. 2001;103:1799-1805.
8. Mizutani A, Okajima K, Uchiba M, Noguchi T. Activated protein C reduces ischemia/ reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood. 2000;95:3781-3787.
9. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987;79:918-925.
10. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
11. Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med. 2003;31:834-840.
12. Perez A, Whang EE, Brooks DC, et al. Is severity of necrotizing pancreatitis increased in extended necrosis and infected necrosis? Pancreas. 2002;25:229-233.
13. Tenner S, Sica G, Hughes M, et al. Relationship of necrosis to organ failure in severe acute pancreatitis. Gastroenterology. 1997;113:899-903.
14. Rydzewska G, Kosidlo S, Gabryelewicz A, Rydzewski A. Tissue plasminogen activator, plasminogen activator inhibitor, and other parameters of fibrinolysis in the early stages of taurocholate acute pancreatitis in rats. Int J Pancreatol. 1992;11:161-168.
15. Izquierdo R, Sandberg L, Squillaci G, et al. Effects of protease inhibitors on coagulation abnormalities in acute canine pancreatitis. Am Surg. 1984;50:317-323.
16. Ranson JH, Lackner H, Berman IR, Schinella R. The relationship of coagulation factors to clinical complications of acute pancreatitis. Surgery. 1977;81:502-511.
17. Shinowara GY, Stutman L, Walters MI, Ruth ME, Walker EJ. Hypercoagulability in acute pancreatitis. Am J Surg. 1963;105:714-719.
18. Guide for the Care and Use of Laboratory Animals. Bethesda, Md: Dept of Health and Human Services, Office of Science and Health Reports; 1985. DHHS publication (NIH) 85-23.
19. Schmidt J, Lewandrowski K, Fernández-del Castillo C, et al. Histopathologic correlates of serum amylase activity in acute experimental pancreatitis. Dig Dis Sci. 1992;37:1426-1433.
20. Schmidt J, Rattner DW, Lewandrowski K, et al. A better model of acute pancreatitis for evaluating therapy. Ann Surg. 1992;215:44-56.
21. Comp PC, Esmon CT. Activated protein C inhibits platelet prothrombin-converting activity. Blood. 1979;54:1272-1281.
22. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A. 1981;78:2249-2252.
23. Esmon CT, Taylor FB Jr, Snow TR. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost. 1991;66:160-165.
24. Murakami K, Okajima K, Uchiba M, et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood. 1996;87:642-647.
25. Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol. 1994;153:3664-3672.
26. Lasson A, Ohlsson K. Consumptive coagulopathy, fibrinolysis and protease-antiprotease interactions during acute human pancreatitis. Thromb Res. 1986;41:167-183.
27. Satake K, Uchima K, Umeyama K, Appert HE, Howard JM. The effects upon blood coagulation in dogs of experimentally induced pancreatitis and the infusion of pancreatic juice. Surg Gynecol Obstet. 1981;153:341-345.
28. Ottesen LH, Bladbjerg EM, Osman M, et al. Protein C activation during the initial phase of experimental acute pancreatitis in the rabbit. Dig Surg. 1999;16:486-495.
29. Kwaan HC, Anderson MC, Gramatica L. A study of pancreatic enzymes as a factor in the pathogenesis of disseminated intravascular coagulation during acute pancreatitis. Surgery. 1971;69:663-672.
30. Arnljots B, Bergqvist D, Dahlback B. Inhibition of microarterial thrombosis by activated protein C in a rabbit model. Thromb Haemost. 1994;72:415-420.
31. Aoki Y, Ota M, Katsuura Y, Komoriya K, Nakagaki T. Effect of activated human protein C on disseminated intravascular coagulation induced by lipopolysaccharide in rats. Arzneimittelforschung. 2000;50:809-815.
32. Isobe H, Okajima K, Uchiba M, et al. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation. 2001;104:1171-1175.
33. 2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin. J Biol Chem. 1991;266:17606-17612.
34. Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K, Wiedermann CJ. Expression and function of the endothelial protein C receptor in human neutrophils. Blood. 2003;102:1499-1505.
35. Nick JA, Coldren CD, Geraci MW, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood. 2004;104:3878-3885.
36. Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med. 2003;31:12-19.
37. Taylor FB Jr, Chang AC, Peer GT, et al. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood. 1991;78:364-368.